Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths

Ann G. Zauber, Ph.D., Sidney J. Winawer, M.D., Michael J. O’Brien, M.D., M.P.H., Iris Lansdorp-Vogelaar, Ph.D., Marjolein van Ballegooijen, M.D., Ph.D., Benjamin F. Hankey, Sc.D., Weiji Shi, M.S., John H. Bond, M.D., Melvin Schapiro, M.D., Joel F. Panish, M.D., Edward T. Stewart, M.D., and Jerome D. Waye, M.D.

ABSTRACT

BACKGROUND
In the National Polyp Study (NPS), colorectal cancer was prevented by colonoscopic removal of adenomatous polyps. We evaluated the long-term effect of colonoscopic polypectomy in a study on mortality from colorectal cancer.

METHODS
We included in this analysis all patients prospectively referred for initial colonoscopy (between 1980 and 1990) at NPS clinical centers who had polyps (adenomas and nonadenomas). The National Death Index was used to identify deaths and to determine the cause of death; follow-up time was as long as 23 years. Mortality from colorectal cancer among patients with adenomas removed was compared with the expected incidence-based mortality from colorectal cancer in the general population, as estimated from the Surveillance Epidemiology and End Results (SEER) Program, and with the observed mortality from colorectal cancer among patients with non-adenomatous polyps (internal control group).

RESULTS
Among 2602 patients who had adenomas removed during participation in the study, after a median of 15.8 years, 1246 patients had died from any cause and 12 had died from colorectal cancer. Given an estimated 25.4 expected deaths from colorectal cancer in the general population, the standardized incidence-based mortality ratio was 0.47 (95% confidence interval [CI], 0.26 to 0.80) with colonoscopic polypectomy, suggesting a 53% reduction in mortality. Mortality from colorectal cancer was similar among patients with adenomas and those with nonadenomatous polyps during the first 10 years after polypectomy (relative risk, 1.2; 95% CI, 0.1 to 10.6).

CONCLUSIONS
These findings support the hypothesis that colonoscopic removal of adenomatous polyps prevents death from colorectal cancer. (Funded by the National Cancer Institute and others.)
I

T HAS BEEN A LONG-STANDING BELIEF THAT screening for colorectal cancer can affect mortality from the disease in two ways: by detecting cancers at an early, curable stage and by detecting and removing adenomas. Detection of early-stage colorectal cancer has been shown to be associated with a reduction in mortality from colorectal cancer in screening trials. However, an adenomatous polyp is a much more common neoplastic finding on endoscopic screening. We previously reported that colonoscopic polypectomy in the National Polyp Study (NPS) cohort reduced the incidence of colorectal cancer. An important question is whether the cancers prevented by colonoscopic polypectomy in the cohort were those that had the potential to cause death. To estimate the effect of colonoscopic detection and removal of adenomatous polyps on mortality from colorectal cancer, we examined mortality in the study cohort during a surveillance period of up to 23 years after colonoscopic polypectomy.

METHODS

STUDY DESIGN

We conducted a long-term follow-up study of the NPS cohort using the National Death Index (NDI) to determine the death rate among patients with adenomatous polyps that had been removed, as compared with mortality from colorectal cancer in the general population and in an internal concurrent control group of patients with nonadenomatous polyps.

The NPS was a multicenter postpolypectomy surveillance study of patients with one or more newly diagnosed adenomas; it involved seven clinical centers that represent a wide range of endoscopic practices (see the Supplementary Appendix, available with the full text of this article at NEJM.org). Patients in the randomized, controlled trial were assigned either to surveillance colonoscopy at 1 and 3 years after polypectomy or to first surveillance colonoscopy at 3 years; both groups were offered surveillance colonoscopy at 6 years. Previous reports have detailed the study design and methods.

PATIENTS

All patients referred for initial colonoscopy at the seven clinical centers between November 1980 and February 1990 who did not have a family or personal history of familial polyposis or inflammatory bowel disease or a personal history of prior polypectomy or colorectal cancer were prospectively evaluated for enrollment in the randomized, controlled trial of surveillance intervals and underwent a protocol-specified colonoscopy. Patients had been referred for colonoscopy because of positive findings on barium enema examination (27%), sigmoidoscopy (15%), fecal occult-blood test (11%), or other tests (10%) or because of symptoms (32%) or a family history (5%) of colorectal cancer. All identified polyps were removed and centrally reviewed according to NPS pathological criteria. Patients were classified at the initial colonoscopy as having adenomatous polyps or only nonadenomatous polyps (i.e., mucosal tags or hyperplastic polyps) by pathological classification at the clinical center (Fig. 1). Patients with newly diagnosed adenomas were eligible for the randomized, controlled study if they underwent a complete colonoscopy to the cecum with removal of one or more adenomas and if all polyps detected were removed. Patients were ineligible if they had no polyps or had gross colorectal cancer, inflammatory bowel disease, malignant polyps (i.e., a polyp removed at colonoscopy that appeared to be benign on endoscopy but that was identified as invasive adenocarcinoma on pathological assessment), or sessile polyps greater than 3 cm in diameter, or if the colonoscopy was incomplete. The current analysis of mortality from colorectal cancer included all patients with adenomas who were eligible for the randomized trial and all patients with only nonadenomatous polyps (Table 1 and Fig. 1).

COMPARISON GROUPS

General Population

To compare the observed mortality in the adenoma cohort with appropriately matched rates in the general population, we used incidence-based mortality to adjust the general-population rates for our exclusions. Incidence-based mortality, which is derived by following back deaths in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) population-based registry program to their diagnosis (http://surveillance.cancer.gov/statistics/ibm), allows mortality to be partitioned by date of diagnosis. We excluded deaths from colorectal cancer in the SEER database that occurred in cases that were diagnosed before the calendar year of enrollment in the NPS and those that were diagnosed within 3 years after enrollment. This 3-year time lag corresponds to the average...
Polypectomy and Prevention of Colorectal-Cancer Deaths

Cancer sojourn time, as estimated from screening studies that use fecal occult-blood tests. The period during which a cancer can be detected by a screening test (e.g., the fecal occult-blood test) before entering a clinical phase is defined as the cancer sojourn time. During the study-enrollment period (from 1980 through 1990), there was a small percentage of people who underwent screening for colorectal cancer, with screening performed predominantly by means of a guaiac fecal occult-blood test. On the basis of the available literature, we estimated an average sojourn time for colorectal cancer of 3 years (range, 2 to 5).

We used SEER*Stat with the SEER registries of nine areas (SEER9), which included data from 1975 forward, for the analysis of incidence-based mortality from colorectal cancer. We used the National Center for Health Statistics database for the analysis of all causes of death in the general population.

**Nonadenoma Cohort as Internal Concurrent Control**

Patients referred for initial colonoscopy at the participating centers from 1980 through 1990 who had only nonadenomatous polyps (including mucosal tags) were used as an internal concurrent control group for the adenoma cohort. All hyperplastic polyps were reviewed in 2007 and were reclassified on the basis of criteria for the serrated polyp pathway.

**Figure 1. Study Enrollment.**

Of the 9112 patients referred for this study, 2602 with adenomatous polyps and 773 with only nonadenomatous polyps were included in the analysis. Diagnosis was made according to pathological classification at the clinical center. Only patients who provided sufficient demographic information (at least first and last names and either Social Security number or the month and year of birth) were matched against data from the National Death Index. These identifiers were not retained for patients with no polyps or with gross cancer; consequently, none of these patients were included in the analysis of mortality. In addition, 30 patients with adenomas and 3 with nonadenomas did not have sufficient demographic information and were not included in the analysis.
END POINTS
To ascertain mortality from colorectal cancer, we matched the NPS patient cohorts against records in the NDI, the registry of all deaths in the United States, from 1980 through 2003.22 NPS records were matched against the NDI data on the basis of name, Social Security number, date of birth, sex, marital status, state of birth, and state of residence. Only records that included sufficient information — at least first and last names and either Social Security number or the month and year of birth — were matched against the NDI data (Fig. 1). The identifiers of date of birth and Social Security number were not collected for patients with no polyps or with gross cancer; consequently, data for these patients could not be matched against the NDI data and are not included in this study. In addition, a small number of patients in the adenoma and nonadenoma cohorts had insufficient information to allow a match with the NDI registry and were excluded from the analysis.

STUDY OVERSIGHT
The human subjects committee of the Memorial Sloan-Kettering Cancer Center approved the NPS. Patients provided authorization to release all medical and pathological reports to the study, as well as written informed consent to participate in the trial. In addition, the committee granted a waiver of authorization to conduct the search of the NDI.

Table 1. Baseline Characteristics of the Adenoma and Nonadenoma Cohorts.*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Adenoma (N = 2602)</th>
<th>Nonadenoma (N = 773)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age — yr‡</strong></td>
<td>62.0±11.1</td>
<td>57.3±12.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age group — no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50 yr</td>
<td>327 (12.6)</td>
<td>193 (25.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>50–59 yr</td>
<td>682 (26.2)</td>
<td>223 (28.8)</td>
<td></td>
</tr>
<tr>
<td>60–69 yr</td>
<td>926 (35.6)</td>
<td>233 (30.1)</td>
<td></td>
</tr>
<tr>
<td>≥70 yr</td>
<td>657 (25.3)</td>
<td>124 (16.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Sex — no. (%)§</strong></td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>Male</td>
<td>1722 (66.2)</td>
<td>466 (60.3)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>878 (33.7)</td>
<td>307 (39.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Race — no. (%)¶</strong></td>
<td></td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>White</td>
<td>2143 (82.4)</td>
<td>640 (82.8)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>178 (6.8)</td>
<td>61 (7.9)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>25 (1.0)</td>
<td>9 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>256 (9.8)</td>
<td>63 (8.2)</td>
<td></td>
</tr>
<tr>
<td><strong>No. of first-degree relatives with colorectal cancer — no. (%)</strong></td>
<td></td>
<td></td>
<td>0.08</td>
</tr>
<tr>
<td>0</td>
<td>2169 (83.4)</td>
<td>669 (86.5)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>376 (14.5)</td>
<td>87 (11.3)</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>57 (2.2)</td>
<td>17 (2.2)</td>
<td></td>
</tr>
<tr>
<td><strong>No. of colonoscopies to clear all detected polyps — no. (%)</strong></td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1</td>
<td>2320 (89.2)</td>
<td>757 (97.9)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>266 (10.2)</td>
<td>16 (2.1)</td>
<td></td>
</tr>
<tr>
<td>≥3</td>
<td>16 (0.6)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Participation in randomized follow-up surveillance study of patients with adenomas — no. (%)</strong></td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Yes</td>
<td>1418 (54.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1184 (45.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. (Continued.)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Adenoma (N = 2602)</th>
<th>Nonadenoma (N = 773)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most advanced adenoma — no./total no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonadvanced</td>
<td>1075/2517 (42.7)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Advanced**</td>
<td>1442/2517 (57.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of adenomas — no./total no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1475/2517 (58.6)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>555/2517 (22.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥3</td>
<td>487/2517 (19.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location of adenomas — no./total no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distal only</td>
<td>1621/2517 (64.4)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Any proximal</td>
<td>896/2517 (35.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal only</td>
<td>377/2517 (15.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distal and proximal</td>
<td>519/2517 (20.6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. NA denotes not applicable.
† Chi-square tests were used for the comparison of categorical variables between groups; Student’s t-test was used for the comparison of mean age.
‡ Data on age were missing for 10 patients in the adenoma cohort.
§ Data on sex were missing for 2 patients in the adenoma cohort.
¶ Race was self-reported. The proportion of blacks in the NPS patient population was consistent with the U.S. Census estimate of blacks at similar ages (9%).
‖ Of the 2602 patients with adenomas, 85 (3.3%) had polyps that were originally classified as adenomatous at the clinical centers but were reclassified as nonadenomatous by NPS pathological review, so the total number of patients with adenomas in this calculation is 2517.
** Advanced adenoma was defined by a diameter of 1.0 cm or more, tubulovillous or villous histologic appearance, or high-grade dysplasia. Of the 1442 patients with advanced adenomas, 895 (62%) had only tubular adenomas that were 1.0 cm or larger.
†† Location of the adenomas was defined as proximal for lesions in the cecum, ascending colon, hepatic flexure, and transverse colon and as distal for lesions in the splenic flexure, descending colon, sigmoid colon, or rectum.

STATISTICAL ANALYSIS

Person-years at risk were calculated for each patient from the date of the initial colonoscopy until death or the last date of follow-up (December 31, 2003), according to NDI records and categorized by age (within 5-year groups), sex, race, calendar year, and calendar year of enrollment in the study. These data on person-years at risk were used in conjunction with the incidence-based mortality from colorectal cancer in the general population, according to SEER9 data, to determine the number of deaths from colorectal cancer that would be expected in the adenoma cohort if the cohort had the same rate of death as that among members of the general population with similar age, sex, race, and calendar-year characteristics and with adjustment for the same exclusions. The observed number of deaths was assumed to follow a Poisson distribution. The standardized incidence-based mortality ratio was derived as the ratio of observed to expected deaths from colorectal cancer, and the exact 95% confidence interval was calculated. A two-sided P value of 0.05 or less was considered to indicate statistical significance. The percent reduction was calculated as the complement of the standardized mortality ratio multiplied by 100. The results are presented for the entire follow-up time, for the first 10 years (0 to 9.9 years), and for 10 or more years of follow-up. The standardized mortality ratio for all causes of death was also calculated.

Fisher’s exact test was used to compare the observed mortality in the adenoma and nonadenoma cohorts in the first 10 years of follow-up. The net cumulative mortality curves specific for colorectal cancer were derived as the complement of the Kaplan–Meier cumulative survival curve. SAS software, version 9.2 (SAS Institute), was used for analyses.

The accuracy of the NDI match to the NPS co-
The characteristics of the 2602 patients with adenomatous polyps are shown in Table 1. In the randomized adenoma cohort, 81% of patients underwent one or more surveillance colonoscopies.9 There were 37,073 person-years at risk in the adenoma cohort. The median follow-up period was 15.8 years, with a maximum of 23 years. Analysis of these deaths served as an assessment of the completeness of the overall cohort match to the NDI for all deaths.

RESULTS

MORTALITY IN THE ADENOMA COHORT

The characteristics of the 2602 patients with adenomatous polyps are shown in Table 1. In the randomized adenoma cohort, 81% of patients underwent one or more surveillance colonoscopies.9 There were 37,073 person-years at risk in the adenoma cohort. The median follow-up period was 15.8 years, with a maximum of 23 years. On the basis of the NDI match, there were 1246 deaths among the 2602 patients (48%). All-cause mortality was lower in the adenoma cohort than in the general population, matched by age, sex, race, and calendar year on the basis of SEER data (standardized mortality ratio, 0.85; 95% confidence interval [CI], 0.81 to 0.90). The NDI match for the 1418 patients in the randomized, controlled trial had 97.5% sensitivity, 99.7% specificity, and 99.4% overall accuracy in classifying deaths.

There were 12 deaths from colorectal cancer in the adenoma cohort (Table 2), as compared with 25.4 expected deaths from the disease in the general population (standardized incidence-based mortality ratio, 0.47; 95% CI, 0.26 to 0.80) (Table 3), corresponding to an estimated 53% reduction.
in mortality from colorectal cancer. The reduction in mortality for the first 10 years of follow-up (0 to 9.9 years) was similar to that for 10 or more years of follow-up (Table 3). The cumulative mortality rate in the adenoma cohort at 20 years was 0.8%, as compared with an estimated 1.5% in the general population (on the basis of SEER9 data) (Fig. 2).

Sensitivity analyses of 2-year and 5-year cancer sojourn times showed a reduction in mortality from colorectal cancer of 56% (P = 0.003) and 44% (P = 0.04), respectively, for the entire 23 years of follow-up. The 51% reduction in mortality for the follow-up period of 10 or more years was not affected by varying the sojourn time.

**MORTALITY IN THE NONADENOMA COHORT**

Of the 773 patients in the NPS with nonadenomatous polyps, 278 (36%) had hyperplastic polyps; there were no serrated polyps with adenomatous change or dysplasia in this cohort. These patients were followed for a total of 12,090 person-years, with a median follow-up period of 16.5 years. Patients with nonadenomatous polyps were similar to those with adenomatous polyps with respect to race and number of first-degree relatives with colorectal cancer. However, they were younger than the adenoma cohort (57 years vs. 62 years, P<0.001) and more likely to be women (40% vs. 34%, P=0.002) and accordingly at lower risk for colorectal cancer (Table 1). There was one death from colorectal cancer at 7.7 years. In the first 10 years after the initial colonoscopy, the observed mortality for colorectal cancer in the adenoma cohort was similar to that in the nonadenoma cohort (0.19% and 0.15%, respectively; relative risk for the adenoma cohort, 1.2; 95% CI, 0.1 to 10.6; P = 1.0) (Table 4).

**DISCUSSION**

We previously found that polypectomy reduced the incidence of colorectal cancer in the NPS cohort. The present study suggests that adenoma removal significantly reduced the risk of death from colorectal cancer, as compared with that in the general population, and in the first 10 years after polypectomy, reduced the risk to a level similar to that in

<table>
<thead>
<tr>
<th>Follow-up Time</th>
<th>Person-Years at Risk</th>
<th>Observed Deaths</th>
<th>Expected Deaths</th>
<th>SMR (95% CI)</th>
<th>Reduction</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>2602</td>
<td>37,073</td>
<td>12</td>
<td>25.4</td>
<td>0.47 (0.26–0.80)</td>
<td>53</td>
</tr>
<tr>
<td>&lt;10 yr</td>
<td>2602</td>
<td>22,903</td>
<td>4</td>
<td>9.1</td>
<td>0.44 (0.14–1.06)</td>
<td>56</td>
</tr>
<tr>
<td>≥10 yr</td>
<td>2031</td>
<td>14,170</td>
<td>8</td>
<td>16.3</td>
<td>0.49 (0.23–0.93)</td>
<td>51</td>
</tr>
</tbody>
</table>

* Data on the general population are from the Surveillance, Epidemiology, and End Results registries of nine areas (SEER9). The standardized mortality ratio (SMR) and percent reduction in mortality are for the adenoma cohort as compared with the general population.
Fisher’s exact test was used to compare the observed mortality in the two cohorts. The mean follow-up time within the first 10 years was 9 years for both the adenoma and nonadenoma cohorts.

Table 4. Comparison of Adenoma and Nonadenoma Cohorts in the First 10 Years after Initial Colonoscopy.*

<table>
<thead>
<tr>
<th>Cohort</th>
<th>No. of Patients</th>
<th>Person-Years at Risk</th>
<th>Observed Deaths</th>
<th>Relative Risk (95% CI)</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoma</td>
<td>2602</td>
<td>22,903</td>
<td>4</td>
<td>1.2 (0.1–10.6)</td>
<td>1.00</td>
</tr>
<tr>
<td>Nonadenoma</td>
<td>773</td>
<td>7,178</td>
<td>1</td>
<td>1.0</td>
<td></td>
</tr>
</tbody>
</table>

* The mean follow-up time within the first 10 years was 9 years for both the adenoma and nonadenoma cohorts.
† Fisher’s exact test was used to compare the observed mortality in the two cohorts.

Our comparison of observed deaths in the adenoma cohort with expected deaths in the general population, based on SEER data that were specific for age, sex, race, and calendar year, may have underestimated the reduction in mortality that may be achieved with colonoscopic polypectomy in screening populations. Because all the patients in the adenoma cohort had adenomas, including 57.3% with advanced adenomas, they represented a higher-risk group than the general population.

The comparison of mortality in the adenoma cohort with that in a concurrent control group of patients in the NPS who did not have adenomatous polyps supported the results of the comparison with estimated mortality in the general population. The patients without adenomas were similar to those with adenomas, except for the findings at initial colonoscopy. The group without a precursor adenoma would be expected to have low mortality from colorectal cancer, and several studies have also shown that patients with no polyps or with nonadenomatous polyps have low rates of colorectal neoplasia after colonoscopy.

A cohort of patients with adenomas in whom polypectomy was not performed would, of course, be a more meaningful comparison group for the patients in the NPS with adenomas, all of whom underwent polypectomy, but such a comparison group would not be an option on either ethical or clinical grounds because of the known potential for adenomas to progress to carcinoma. We addressed this comparison using a microsimulation model of the mortality effect had the adenomas not been removed and the natural history of the adenoma–carcinoma sequence had proceeded without intervention. This model, the MISCAN-Colon model of the Cancer Intervention and Surveillance Modeling Network (CISNET) (http://cisnet.cancer.gov), showed an even larger reduction in mortality from polypectomy than the comparison with the SEER incidence-based mortality rates (see the Supplementary Appendix).

Although the NPS does not address the effectiveness of screening colonoscopy in the general population, our findings provide an indirect estimate of the effect of removing adenomas, which is the primary interventional measure in screening colonoscopy. Studies and commentaries have raised issues regarding the magnitude of the effect of colonoscopy on the incidence of and mortality from colorectal cancer. A recent study from Germany showed a large effect of colonoscopy on the incidence of colorectal cancer. In two Canadian studies, the mortality reduction from colonoscopy in community practice was largest when the colonoscopy was performed by a gastroenterologist and when the examination was complete. The magnitude of the reduction in mortality among the patients in the NPS after polypectomy is probably due to high-quality colonoscopy performed by well-trained gastroenterologists. These issues will be more precisely understood after completion of long-term randomized, controlled trials of screening colonoscopy in the general population that have recently been initiated in northern Europe (Nordic-European Initiative on Colorectal Cancer; ClinicalTrials.gov number, NCT00883792), in Spain (ClinicalTrials.gov number, NCT00906997), and by the Veterans Administration in the United States (ClinicalTrials.gov number, NCT01239082); the incidence and mortality end points will not be available for at least 10 or more years.

This prospective study has some limitations. First, a small number of trained endoscopists performed the colonoscopies according to a study protocol that required examination to the cecum, adequate preparation, careful inspection of the colon, and removal of all identified polyps, features that are consistent with reports of high-quality performance. Consequently, the NPS observations may not be generalizable to present community practice, for which reported incidence rates of colorectal cancer after polypectomy are higher than those reported in the NPS.

Comparisons with mortality from colorectal cancer in the general population, based on the SEER data, were limited by our inability to adjust for differences between the NPS cohort and the general population in risk factors, behaviors, ac-
cess to health care, or quality of health care. All-
cause mortality was lower for the patients enrolled
in the NPS than for the general population; the
difference may be attributable to better access to
medical care (which included colonoscopy) in the
NPS study and the fact that the study patients were
in sufficiently good health (especially with respect
to cardiovascular disease) to have been referred for
colonoscopy during the period from November
1980 through February 1990.

Our comparison of the two NPS cohorts (pa-
tients with and those without adenomas) was
limited by the very small number of deaths from
colorectal cancer, as reflected by the wide confi-
dence intervals, indicating either a large decrease
or a large increase in the relative risk of death from
colorectal cancer for the patients with adenomas,
compared with those with only nonadenomas.

An additional limitation of the study is that it
did not take account of potential changes in life-
style over time. After detection and removal of an
adenoma, patients may stop smoking, modify their
diet, control their weight, increase their physical
activity, and take multivitamins and nonsteroidal
antiinflammatory drugs to prevent recurrence of
adenomas and prevent colorectal cancer.

Deaths that occurred during the study were as-
certained with the use of data from the NDI. These
data are based on information from death certifi-
cates, which do not include the site in the colorec-
tum of the original cancer. Consequently, mor-
tality rates associated with proximal and distal
cancers could not be compared in this study.

Finally, 81% of the patients in the randomized
adenoma cohort underwent surveillance colonos-
copies after polypectomy. Consequently, the poly-
pectomy effect for these patients would include
the effect of surveillance colonoscopies as well.

In conclusion, we previously reported a lower-
than-expected incidence of colorectal cancer in
patients after the removal of adenomatous polyps,
and this study shows that polypectomy results in
reduced mortality from colorectal cancer. These
combined findings indicate that adenomas identi-
ified and removed at colonoscopy include those that
are clinically important, with the potential to pro-
gress to cancer and cause death. A demonstrated
reduction in mortality with colonoscopic polypec-
tomy is a critical prerequisite for continued recom-
endations of screening colonoscopy in clinical prac-
tice while we wait for the results of random-
ized, controlled trials of screening colonoscopy.

The views expressed in this article are those of the authors and
do not necessarily represent the official views of the National
Cancer Institute or the National Institutes of Health.

Supported by grants from the National Cancer Institute (R01
CA026852 and R01 CA046940, to Drs. Zauber, Winawer, O’Brien,
Bond, Schapiro, Panish, Stewart, and Waye; R01 CA079572, to
Drs. Zauber, Winawer, O’Brien, and Bond; and U01 CA095426,
U01 CA119553, and U01 CA152990, to Drs. Zauber, Winawer,
O’Brien, Landsorp-Vogelaar, and van Ballegooijen); and by funding
from the Society of Memorial Sloan-Kettering Cancer Center (to
Dr. Zauber), the Tavel-Reznik Fund (to Drs. Zauber and Winawer),
and the Cantor Colon Cancer Fund (to Dr. Winawer).

No potential conflict of interest relevant to this article was
reported.

Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.

We thank Michael Bretthauer, M.D., Ph.D., from the Department
of Gastroenterology, Oslo University Hospital at Rikshospitalet,
OslO, for his editorial review of an earlier draft of the article.

REFERENCES

1. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the
erly detection of colorectal cancer and adenomatous polyps, 2008: a joint guide-
line from the American Cancer Society, the US Multi-Society Task Force on Colorectal


3. Kronborg O, Fenger C, Olsen J, Jør-
gensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet


12. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortal-
ty trends by factors associated with diagnosis: an application to female breast


14. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interven-
tions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenari-


